No — not if you mean pharmaceutical-grade peptides like semaglutide, BPC-157, or CJC-1295/ipamorelin. In the United States, a peptide intended to treat a condition or change how your body works is regulated as a drug, and drugs require a prescription. So — can you buy peptides over the counter at all? Legally, only in two much narrower categories: cosmetic peptides in skincare products, which are regulated as cosmetics, and dietary-supplement peptides such as collagen, which are regulated under supplement law.
Everything else sold without a prescription — the injectable vials sold under research-use-only labels — belongs to a gray market the FDA has been moving against, most recently with warning letters to peptide sellers in late 2024.
Can you buy peptides over the counter legally?
Two categories of peptides are legally sold over the counter: cosmetic peptides and dietary-supplement peptides. Neither is the injectable therapeutic product most people are asking about.
Cosmetic peptides are ingredients in creams and serums that work at the skin's surface. Because they are regulated as cosmetics rather than drugs, they face no premarket approval, and you can buy them at any drugstore or online. One catch: marketing claims that a product changes the body's structure or function can legally reclassify a cosmetic as an unapproved drug — which is why skincare marketing stays carefully vague.
Dietary-supplement peptides — collagen peptides and amino-acid blends are the common examples — are regulated under dietary-supplement law (DSHEA), which is considerably less strict than pharmaceutical regulation. Manufacturers are responsible for safety, but no agency reviews these products before they reach the shelf.
Anything injectable, and anything marketed for therapeutic effects, sits on the other side of the prescription line.
Why therapeutic peptides require a prescription
Therapeutic peptides don't stop at the skin's surface — they reach into hormone pathways, immune activity, and the body's tissue-repair systems — which is why U.S. law treats them as drugs requiring medical supervision.
Peptide drugs are a large and growing class. Roughly 100 peptides have been authorized by the FDA since insulin in 1921, including analogues acting on pathways from GLP-1 and GIP to GHRH, CCK, ACTH, and α-MSH (Al Musaimi, Biomolecules 2024). Thirty-four peptide approvals came between 2016 and 2024, and in 2024 four of the FDA's 50 novel drug approvals were peptides or oligonucleotides — two of each (Al Musaimi et al., Pharmaceuticals 2025).
Many of the peptides people ask about, though — BPC-157, CJC-1295/ipamorelin, and similar compounds studied for tissue repair or growth-hormone signaling — are not FDA-approved drugs at all. Where available, they come as compounded prescription medications prepared by a pharmacy for an individual patient. Either way — fully approved drug or compounded one — no legitimate channel sells it over the counter.
What research-use-only labels really mean
The injectable peptides sold online without a prescription carry labels stating the contents are meant for laboratory research and are not intended for people. That wording is the seller's own disclaimer, and it tells you the product was never manufactured, tested, or approved for use in a human being.
The disclaimer is also weaker legal cover than sellers imply. The FDA has scrutinized companies that use research labels while marketing in ways that suggest human use — dosing guidance, wellness claims — and in late 2024 it issued warning letters to peptide sellers on exactly those grounds, citing violations of the Federal Food, Drug, and Cosmetic Act. The letters are public in the FDA's warning letter database.
Buying from an unverified supplier carries documented risks:
- Identity — the vial may not contain the compound on the label.
- Purity — actual peptide content can run far below what's claimed.
- Contamination — non-sterile manufacturing is a real hazard for anything injected.
- Dosing accuracy — without verified concentration, you can't know what you're measuring.
- No recourse — a seller operating outside the law owes you nothing when something goes wrong.
Purity is not a cosmetic concern. A 2024 FDA-CRCG workshop on peptide drug products examined the ways peptide impurities can set off unwanted immune responses (Lee et al., AAPS J 2026) — and that workshop concerned pharmaceutical products under full oversight; in an unregulated vial, the same risk has no one watching it. Legitimate quality documentation means third-party certificates of analysis with HPLC and mass-spectrometry testing; a seller who won't produce them has answered your question.
How the three markets compare
The supplement shelf, the gray-market website, and the pharmacy counter differ on every axis that matters:
| Supplement aisle | Research-use-only websites | Compounded prescription | |
|---|---|---|---|
| Typical products | Collagen powder, peptide skincare, amino-acid blends | Injectable peptide vials sold without a prescription | Medication prepared for you against a provider's prescription |
| Legal basis | Cosmetic and dietary-supplement law | Lawful only for genuine laboratory research; unlawful when sold for human use | Federal and state pharmacy law (Section 503A) |
| Oversight | No premarket approval; FDA acts on violations after the fact | None for human use | State-licensed pharmacy and licensed prescriber |
| Quality testing | Varies by brand; third-party testing optional | Whatever the seller chooses to disclose | Identity, purity, and sterility standards |
| Reasonable role | Skin and general wellness support | Laboratory research | Therapy under medical supervision |
What changed with compounding, 2023–2025
Beginning in October 2023 and running into 2025, a series of FDA actions sharply narrowed which peptides compounding pharmacies could legally prepare. Section 503A limits a compounding pharmacy to substances that are active ingredients of approved drugs, that carry a USP monograph, or that sit in Category 1 of the FDA's proposed bulk-substances list; Category 2 is the other bucket — substances flagged for safety concerns that pharmacies should not compound. (For how compounding pharmacies work, see how compounded medications are made.)
The 2023 recategorization put BPC-157 in Category 2, and the agency pulled CJC-1295 and AOD-9604 from compounding eligibility the same year. The FDA's Pharmacy Compounding Advisory Committee (PCAC) also formally reviewed ipamorelin, CJC-1295, AOD-9604, and ibutamoren (MK-677), citing limited safety data, impurity concerns, and potential immunogenicity. (One correction to the usual reporting: ibutamoren is a small-molecule secretagogue, not a peptide.)
The GLP-1 story ran on a parallel track. Semaglutide and tirzepatide — the active ingredients of well-known brand-name medications — could be compounded broadly while those drugs were in shortage. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, winding down those flexibilities and narrowing compounded access. Some clinics dropped particular peptides from their menus; others reworked their protocols. Compounded semaglutide remains available in specific circumstances by individual prescription, dispensed as a compounded medication, which is different from an FDA-approved product: the formulation itself is not FDA-approved.
Where the rules stand after July 2026
The most recent development points the other direction. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend several peptides for the 503A bulks list — the list that would permit pharmacy compounding: BPC-157 by a vote of 8–6–1, along with TB-500, KPV, Semax, MOTS-c, and Epitalon. One compound, DSIP, was rejected by a 6–7–1 vote.
Two caveats keep this in perspective: the votes are advisory, with notice-and-comment rulemaking still pending, and a committee tally does not decide your care. A licensed provider may still prescribe a compounded peptide where the law permits — that decision is between you and your doctor.
The legitimate route, in person or online
The legal way to obtain a therapeutic peptide has three steps: a licensed provider (physician, nurse practitioner, or physician associate) evaluates your health history and medications, orders labs if needed, and writes a prescription if treatment is appropriate; a licensed pharmacy then prepares and dispenses it. Pharmacies are licensed by state boards — the FDA separately registers larger 503B outsourcing facilities — and test what they dispense for identity, purity, and sterility.
This path costs more than a gray-market vial; the difference buys a clinician who has seen your history and a pharmacy accountable for what's in the syringe.
Telehealth is a fully legal version of the same path, with one non-negotiable requirement: a telehealth doctor must be licensed in your state. With that in place, a virtual visit plus a licensed pharmacy is the same regulatory structure as an in-person clinic — just delivered over video.
Promise works exactly this way. Its products are compounded medications prepared by a licensed U.S. compounding pharmacy, available only after a clinician in Promise's prescriber network evaluates your request. A licensed provider reviews every request and prescribes or declines based on medical eligibility; not everyone qualifies.
What the over-the-counter options can do
The legal OTC peptides are not placebos — but their evidence is specific, and their effects are modest. Collagen peptides, the most studied of the group, are hydrolyzed collagen broken into smaller chains the body can absorb.
Two recent randomized controlled trials put numbers on them. In one 2025 placebo-controlled trial, 77 healthy women took bioactive collagen peptides at 5,000 mg/day over 12 weeks and showed significant improvements in dermal density, skin hydration, and water loss versus placebo (p<0.05), with benefits persisting through a 4-week washout; dermal thickness increased while the epidermis was unchanged (Wang et al., J Cosmet Dermatol 2025). In a second 2025 trial, 70 healthy adults took 1,650 mg/day of a low-molecular-weight collagen formulation — including 74.25 mg of the functional dipeptide Gly-Pro — for 8 weeks and showed reduced wrinkle depth, improved elasticity and hydration, and increased dermal density, maintained through a 2-week washout, with no adverse events (Lee et al., J Microbiol Biotechnol 2025). Both trials were industry-funded — authors employed by or affiliated with the manufacturers — so read the results as promising rather than settled.
Copper peptides (GHK-Cu) are commonly described in connection with collagen production and skin repair, though the evidence is early-stage. In one 2024 study, GHK-Cu packaged in a liposomal nanocarrier produced marked antioxidant and anti-inflammatory effects in skin cells, working through the Nrf2 and SIRT1 pathways involved in skin aging — but this was an in vitro study of a delivery system, not a human trial (Wang et al., Colloids Surf B 2024). Topicals act at the skin's surface; expect subtle texture and firmness changes over weeks, not a transformation.
Food-derived bioactive peptides — formed when dairy, egg, and fish proteins are digested, and concentrated into supplements marketed for blood-pressure and immune support — round out the category. The evidence base is mixed, and any effects tend to be modest.
Red flags when a seller is cutting corners
A few signals reliably separate legitimate sellers from the rest. Any one of these is reason to walk away:
- Unrealistic claims. "Lose 30 pounds in a single month" or "turn back aging 20 years" are marketing inventions. Legitimate products make modest claims on timelines of weeks to months.
- No third-party testing. Reputable companies provide certificates of analysis with HPLC and mass-spectrometry results. Refusal to show them is disqualifying.
- No contact information. A real business shows a physical address, a phone number, and responsive service. Email-only sellers with offshore addresses are hiding for a reason.
- Prices far below market. A drastically cheaper vial usually means dilution, contamination, or counterfeit product.
Importing peptides and traveling with them
Buying from overseas doesn't route around U.S. law. U.S. Customs has the authority to seize peptide shipments that fall short of FDA standards, and legality in the country of origin does not cure a U.S. violation — you can lose the money and face penalties.
Traveling with prescription peptides is a different, manageable situation: carry your prescription documentation, keep medications in their original pharmacy containers, and check the rules before you fly — a peptide that's legal in the U.S. may be banned where you're headed.
Where that leaves you
The over-the-counter question has a clean answer. Collagen and cosmetic peptides: yes, legally and easily, with modest and specific benefits. Therapeutic peptides: prescription-only, through a licensed provider and a licensed pharmacy, in an office or over video. The vials in between — sold to anyone with a credit card under a research label — are the one category with no oversight, no verified testing, and no one accountable for what's in them.
The regulatory ground is still moving — the July 2026 advisory votes may eventually widen what pharmacies can compound, but rulemaking is pending. Whether a compounded peptide makes sense for you is a conversation for a licensed provider who has seen your health history — and the answer may be no.
This article is educational and is not medical advice. Whether any compounded peptide is appropriate for you is a decision to make with a licensed provider.